# OLAParib COmbinations

> **NCT02576444** · PHASE2 · TERMINATED · sponsor: **Joseph Paul Eder** · enrollment: 67 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** AZD2281
- **DRUG:** AZD5363
- **DRUG:** AZD1775
- **DRUG:** AZD6738

## Key facts

- **NCT ID:** NCT02576444
- **Lead sponsor:** Joseph Paul Eder
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-11
- **Primary completion:** 2019-11-18
- **Final completion:** 2019-11-18
- **Target enrollment:** 67 (ACTUAL)
- **Why stopped:** The study was paused during COVID and without the ability to initiate the 4th arm in the study, the decision was to terminate the study in 2022.
- **Last updated:** 2022-12-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02576444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02576444, "OLAParib COmbinations". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02576444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*